Trials / Completed
CompletedNCT00426140
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Patupilone |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2006-11-01
- First posted
- 2007-01-24
- Last updated
- 2020-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00426140. Inclusion in this directory is not an endorsement.